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Abstract
The prevalence of antiphospholipid and antinuclear antibodies in 102 patients with at least three unexplained miscarriages before a gestational age of 12 weeks, or at least one intrauterine fetal death after 12 When patients with lupus-like disease or thrombosis were excluded the prevalence of antinuclear antibodies in patients (3/91) was not significantly higher than that in the control group (1/102, p=0 269).
Two patients had antibodies to extractable nuclear antigens (specificity (Ro)SSA, table 3). Both had lupus-like disease and were positive for antinuclear antibodies, the lupus anticoagulant, and anticardiolipin antibodies. No congenital heart block had been noted in previous pregnancies of these patients. There were no patients with anti-RNP, anti-Sm, or anti-(La)SSB antibodies.
One patient without lupus-like disease or thrombosis showed antibodies to double stranded DNA. She had a third trimester intrauterine death. Anticardiolipin antibodies were low positive for IgM. Antinuclear antibodies and antibodies to extractable nuclear antigens could not be shown.
Discussion
This study shows an antiphospholipid antibody prevalence of 21% for anticardiolipin antibodies and 5% for the lupus anticoagulant in a group of 102 patients with at least three spontaneous miscarriages before a gestational age of 12 weeks, or with at least one intrauterine fetal death after 12 weeks. Table 5 shows the wide range of antiphospholipid antibody prevalences in patients with fetal loss and no underlying disorder, as found in nine studies, with values ranging from 8 to 50% for anticardiolipin antibodies and from 3 to 48% for the lupus anticoagulant. Identification of patients positive for antiphospholipid antibodies is of importance because several reports have described successful pregnancies in patients with antiphospholipid antibodies, treated during pregnancy.22 23 This study provides an explanation for the wide variation in prevalence reported for antiphospholipid antibodies by showing that the prevalences of anticardiolipin antibodies and the lupus anticoagulant decreased from 21 to 14% and from 5 to 0%, respectively, after exclusion of all patients with symptoms suggestive of a lupus-like disease or a history of thrombosis, or both, known to be associated with antiphospholipid antibodies. Moreover, when these patients were excluded, the significant difference initially found between anticardiolipin antibodies in patients and controls 
